Clinical Trial Update: Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating olaparib and bevacizumab in relapsed small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Se-Hoon Lee | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED